Takizawa, Tsubasa

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Neurology) ( Shinanomachi )

Position

Assistant Professor/Senior Assistant Professor
Scopus Paper Info  
Paper Count: 103 Citation Count: 1906 h-index: 23

Click to view the Scopus page. The data was downloaded from Scopus API in September 06, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Career 【 Display / hide 】

  • 2010
    -
    2012

    Kawasaki Municipal Hospital

  • 2016

    Keio University, School of Medicine Department of Internal Medicine (Neurology), Instructor

  • 2016
    -
    2018

    Massachusetts General Hospital, Harvard Medical School

  • 2018
    -
    2020

    Keio University, School of Medicine Department of Internal Medicine (Neurology), Instructor

  • 2020
    -
    Present

    Keio University, School of Medicine Department of Internal Medicine (Neurology), Assitant Professor

Page Top ▲

Academic Background 【 Display / hide 】

  • 2004
    -
    2010

    Keio University, School of Medicine

  • 2012
    -
    2016

    Keio University, Graduate School of Medicine

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / General internal medicine

  • Life Science / Neurology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Migraine

  • Neurology

  • Cluster Headache

  • Headache

Page Top ▲
 

Papers 【 Display / hide 】

  • Clinical and social burden of migraine in Japanese males: a cross-sectional comparison with females without menstrual migraine.

    Tsubasa Takizawa, Keiko Ihara, Reiko Yoshikawa, Kanae Togo, Takahiro Kitano, Masahiro Iijima

    The journal of headache and pain 27 ( 1 )  2026.12

    ISSN  11292369

    　View Summary

    BACKGROUND: Migraine is globally more prevalent in females; however, the clinical and social burden among males remains insufficiently characterized. This study aimed to describe the clinical features and social burden of migraine in Japanese males to identify sex-specific migraine profiles. METHODS: A cross-sectional, population-based web survey was conducted among Japanese adults aged ≥ 18 years diagnosed with migraine according to modified criteria from the International Classification of Headache Disorders, Third Edition (ICHD-3). Participants were grouped by sex; females diagnosed with menstrual migraine (MM) were excluded to minimize hormonal confounding. Key outcomes included pain intensity (Visual Analog Scale [VAS]), pain duration, and social burden assessed using validated instruments: Migraine Interictal Burden Scale (MIBS-4), Migraine Disability Assessment (MIDAS), Migraine-Specific Quality of Life Questionnaire (MSQ), and Work Productivity and Activity Impairment for Migraine (WPAI-M) scores. RESULTS: Of 266,392 individuals screened, 18,750 completed the survey; 4,161 males and 9,997 females (excluding those with MM) were included in the analysis. Males were older (mean± standard deviation age: 43.9 ± 12.4 vs. 40.9 ± 12.2 years) and reported more lifestyle-related triggers (e.g., alcohol, irregular eating, and overexercise). Males, compared to females, experienced greater pain intensity (VAS: 57.1 ± 16.7 vs. 54.9 ± 19.6; p < 0.001) but shorter pain duration (6.3 ± 9.4 vs. 7.9 ± 12.4 h; p < 0.001). MIDAS scores were comparable (6.3 ± 10.8 vs. 6.0 ± 9.6; p = 0.283), while MIBS-4 scores were higher in males (4.0 ± 3.5 vs. 3.3 ± 3.3; p < 0.001). MSQ scores were lower in males for domains of interference (83.5 ± 20.0 vs. 85.4 ± 18.3; p = 0.001) and emotional function (80.2 ± 20.9 vs. 81.8 ± 20.3; p = 0.007). Work-related impairment was more pronounced in males than in females, with higher absenteeism (4.7 ± 14.1 vs. 3.4 ± 12.7; p = 0.001), presenteeism (31.5 ± 22.9 vs. 29.5 ± 23.1; p = 0.007), and overall work impairment (33.6 ± 24.6 vs. 30.9 ± 24.3; p = 0.001). Preventive medication use was higher in males (oral: 40.8% vs. 34.3%; injectables: 3.3% vs. 1.7%). CONCLUSION: Males with migraine exhibited a greater burden in terms of pain intensity and functional impairment relative to females without MM. These findings support the development of sex-specific and individualized management strategies that incorporate both pharmacological and lifestyle interventions to reduce disease burden and enhance patient-centered care. TRIAL REGISTRATION: Not applicable.

  • Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review.

    Keiko Ihara, Yu-Hsiang Ling, Yuya Kano, Tsubasa Takizawa, Woo-Seok Ha, Mieko Inagaki, Mi Ji Lee, Byung-Kun Kim, Yen-Feng Wang, Chia-Chun Chiang, Shih-Pin Chen, Shuu-Jiun Wang, Min Kyung Chu, Takao Takeshima

    Current pain and headache reports 30 ( 1 )  2026.12

    ISSN  15313433

    　View Summary

    PURPOSE OF REVIEW: Despite the established efficacy and safety of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) worldwide, evidence from East Asian countries remains limited and may differ from that in Western countries. RECENT FINDINGS: This narrative review comprehensively summarises clinical trials and real-world studies on CGRP mAbs in East Asian populations. A total of 12 clinical trials and 23 real-world studies on galcanezumab, fremanezumab, and erenumab in East Asia were identified through MEDLINE and manual searches. After reviewing each country’s regulations on CGRP mAb usage, we summarised the findings across several categories and compared them with reports from Western countries: effectiveness, adverse events, patient-reported outcome measures, associated symptoms, patient satisfaction, switching, responder characteristics, and discontinuation. Although effectiveness and safety were comparable, notable differences regarding evidence on switching and responder characteristics were observed, likely attributable to variations in inclusion criteria and study design. Overall, the effectiveness and safety profiles of CGRP mAbs in Japan, South Korea, and Taiwan are comparable to those reported in Western countries. However, differences in regulatory policies significantly influenced the findings of real-world reports, highlighting the importance of region- and country-specific evidence.

  • Current landscape of migraine care with expert consensus from East Asia.

    Shuu-Jiun Wang, Tsubasa Takizawa, Jiying Zhou, Mi Ji Lee, Daisuke Danno, Min Kyung Chu, Byung-Kun Kim

    The journal of headache and pain 27 ( 1 )  2026.12

    ISSN  11292369

    　View Summary

    Migraine is a debilitating neurovascular disorder affecting over one billion people globally. While reported prevalence in Asia is lower than in Western countries, significant regional variations and unique clinical presentations necessitate a tailored approach to management. From the Advisory Board Meeting of the East Asian Network for Migraine, expert insights and current literature from China, Japan, South Korea, and Taiwan were synthesized to establish a unified perspective on the epidemiological and sociocultural contexts of the region. Patients in these East Asian countries exhibit distinct clinical features, such as a lower frequency of migraine with aura and photophobia, but a higher incidence of osmophobia compared to Western populations. Despite these clear phenotypic differences, significant gaps in care persist. Acute treatments like triptans remain underutilized, and while emerging CGRP-targeting therapies show promise, their adoption is hindered by high costs and limited accessibility. Furthermore, the region faces critical challenges, including a lack of region-specific clinical trials, culturally appropriate assessment tools, and unified clinical guidelines. Optimizing migraine care in East Asia requires a shift toward personalized, culturally sensitive strategies. Experts reached a consensus on the urgent need for collaborative research to address existing disparities and improve patient outcomes. By aligning clinical practice with the unique sociocultural landscapes of these nations, this statement provides a foundational framework for enhanced policy development and improved migraine management across East Asia.

  • Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study.

    Tsubasa Takizawa, Ryo Takemura, Kaname Ueda, Yasuhiro Miki, Chie Hashimoto

    Pain and therapy 15 ( 4 ) 1065 - 1083 2026.08

    ISSN  21938237

    　View Summary

    INTRODUCTION: Understanding real-world calcitonin gene-related peptide monoclonal antibodies' (CGRP mAbs) use in patients with migraine is necessary to potentially guide treatment strategies. METHODS: This retrospective cohort study analyzed administrative claims data from the IQVIA claims data for Japan. It included CGRP mAb-naïve individuals with confirmed migraine diagnosis and ≥ 1 CGRP mAb prescription (January 2021-June 2023). Index date was the first CGRP mAb prescription. Patient characteristics, treatment patterns, adherence (proportion of days covered ≥ 0.80), persistence, and migraine-related direct costs were assessed. Persistence was measured as the proportion of patients continuing treatment for ≥ 3 or ≥ 6 months (≤ 90-day gap between fills). Factors predicting adherence to CGRP mAb treatment were assessed using multivariate logistic regression. Subgroup analyses were conducted for galcanezumab users. RESULTS: Of the 1781 patients included (mean age 41.8 years [standard deviation, SD 10.3]; 79.3% female patients), 55.0% received galcanezumab, followed by fremanezumab (29.7%), and erenumab (15.3%). The prescription rates of concomitant acute and oral preventive medications were 86.1% and 51.3%, respectively, in the first 3 months after initiating CGRP mAb treatment but numerically decreased to 49.8% and 22.5%, respectively, in the fourth to sixth month. The index CGRP mAb persistence rates were 91.9% for ≥ 3 months and 76.9% for ≥ 6 months, and adherence rate was 51.7%. Multiple positive and negative predictors of adherence to CGRP mAbs were observed. Index to 3 months after initiating index CGRP mAbs, the median average monthly migraine-related costs were JPY 75,320 (Q1, Q3 61,593, 89,843) (USD 592), and non-CGRP mAb migraine-related costs were JPY 15,702 (Q1, Q3 8845, 27,848) (USD 123). These costs tended to reduce or plateau for up to 12 months thereafter. The galcanezumab subgroup showed a similar trend. CONCLUSIONS: CGRP mAb adherence and ≥ 6 months persistence rates were 51.7% and 76.9%, respectively, in CGRP mAb-initiating adults with migraine in Japan. During CGRP mAb treatment, acute and oral preventive medication prescription rates appeared to reduce, while direct costs initially increased but appeared to reduce from the post-initiation peak and plateau over time, although the underlying reasons could not be determined from claims data.

  • Extent of intramedullary short tau inversion recovery signal change predicts traumatic cervical spinal cord injury outcomes in surgically treated older adults: a multicenter study in Japan.

    Takizawa T, Ikegami S, Uehara M, Oba H, Yokogawa N, Sasagawa T, Nakashima H, Segi N, Ito S, Funayama T, Eto F, Yamaji A, Watanabe K, Nori S, Takeda K, Furuya T, Yunde A, Nakajima H, Yamada T, Hasegawa T, Terashima Y, Hirota R, Suzuki H, Imajo Y, Tonomura H, Sakata M, Hashimoto K, Onoda Y, Kawaguchi K, Haruta Y, Suzuki N, Kato K, Uei H, Sawada H, Nakanishi K, Terai H, Tamai K, Kuroda A, Inoue G, Yurube T, Kakiuchi Y, Kiyasu K, Tominaga H, Iizuka Y, Takasawa E, Akeda K, Takegami N, Funao H, Oshima Y, Kaito T, Sakai D, Yoshii T, Ohba T, Otsuki B, Seki S, Miyazaki M, Ishihara M, Okada S, Imagama S, Kato S

    Asian spine journal  2026.07

    ISSN  1976-1902

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Cognitive neuroscience study on the effects of barometric pressure changes on pain: Dissociating physiological and psychological factors

    2026.06
    -
    2028.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), No Setting

    　View Summary

    頭痛患者は極めて多く、痛みや気分の揺らぎによるパフォーマンス低下は社会的損失を招いている。頭痛患者の中には「予測」が引き金となる心理的痛みを持つ者が多く含まれ、特に気圧変化との関連が注目されるが、気圧変化の数日前から頭痛が生じるメカニズムは未解明である。本研究では、気圧カプセルを用いた自律神経の予測機能と頭痛の関係を調べる実験と、独自アプリによる気圧変動と頭痛の観察研究を通じて、生理的痛みと心理的痛みの分離を目指す。気候変動が心身に及ぼす影響の研究が遅れている現状を打破し、治療抵抗性と扱われドクターショッピングに陥る患者の原因解明と、臨床的に適切な指針の提供を目指す。

  • HANAC症候群におけるiPS細胞樹立とβ１インテグリンシグナル作動薬による治療法の確立

    2025.04
    -
    2028.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), No Setting

    　View Summary

    一部の遺伝性脳小血管病では、基底膜を構成するアミノ酸が他のアミノ酸に置換され、コラーゲンの三重らせん構造が崩れることが原因でラクナ梗塞、白質病変など脳小血管病変をきたす。ただし、その機序の詳細は解明されていない。我々はこれまでに、コラーゲンIVの受容体であるβ１インテグリンの機能阻害やコンディショナルノックアウトにより、遺伝性脳小血管病と同様の血栓形成、出血性変化、白質病変の原因となる血液脳関門の破綻が惹起される現象とその機序を報告した。本研究はコラーゲンIV変異による血液脳関門の障害機序を評価するとともに、血管内皮細胞内シグナルの調節に基づく遺伝性脳小血管病の治療確立を目標とする。

  • Effects of changes in barometric pressure on mood fluctuations and somatisation: Basic and clinical approaches

    2024.04
    -
    2028.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), No Setting

    　View Summary

    我が国で頭痛やめまいの症状を持つ患者数は3,000万人を超えると言われており，それに伴う気分の揺らぎに伴うパフォーマンスの低下は，社会全体の活動低下を招いている．これらの患者のなかには，心的ストレスが原因となって身体の不調を訴える症例が多く含まれているが，なぜそのような身体化の症状が生じるかは十分に解明されていない．本研究では，健常者・身体症状症・片頭痛・メニエール病の患者を対象として，自律神経活動，身体状態の変化を感知する内受容感覚，予測的情報処理に基づく信念形成の特性に着目し，気圧変化に対する身体・認知特性を明らかにする．そして，症状改善に向けたプロトコルの開発に取り組む．

  • Investigation of the Current Epidemiology and Biomarkers of Migraine

    2024.04
    -
    2027.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), No Setting

    　View Summary

    CGRP関連抗体薬が2021年に上市され、片頭痛診療は大きな変革期を迎えている。そのような中、わが国における頭痛・片頭痛の最新の疫学を明らかにすることは重要と考える。
    片頭痛について、有用なバイオマーカーは確立されていない。
    本研究では、頭痛・片頭痛についての疫学調査を実施する。さらには片頭痛のバイオマーカーの検索などを試みる。

  • Investigation of anti-CGRP monoclonal antibodies and novel therapeutics for migraine

    2022.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, TAKIZAWA Tsubasa, Grant-in-Aid for Early-Career Scientists, Principal investigator

    　View Summary

    We reported real-world evidence on anti-CGRP monoclonal antibodies (CGRP mAb) at Keio University Hospital. The 50% response rate ranged from 40% to 60%, and the 100% response rate was approximately 10%. Characteristics of responders included older age, fewer failures with previous preventives, and no history of autoimmune diseases. Furthermore, a survey conducted among physician members of the Japanese Headache Society revealed that many physicians set stricter criteria for initiating CGRP mAb than those recommended in the guideline (monthly migraine days greater than or equal to 4, and failure of greater than or equal to 1 conventional preventive medication).
    As part of our investigation into novel treatments, we examined the effect of the antiepileptic drug lacosamide on cortical spreading depolarization, an in vivo model of migraine. We found that lacosamide had a suppressive effect in female mice.

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • Young Investigator Award, Keio University School of Medicine Alumni Association (Sanshikai)

    2024, Keio University School of Medicine, Sanshikai

  • Frontiers in Headache Research Scholarship

    2018, American Headache Society

  • Kitamura Award

    2014, The Japanese Headache Society

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2026

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2026

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2025

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2025

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2024

display all >>

Page Top ▲